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effects in humans – A Literature Search. 
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1.) InoCardia Ltd, Technocentre, Puma Way, Coventry, CV1 2TT, UK 
2.) Centre for Applied Biological & Exercise Sciences, Faculty of Health & Life 
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Abstract 
Adverse drug effects on the cardiovascular system is a major cause of compound 
attrition throughout compound discovery and development.  There are many 
ways by which drugs can affect the cardiovascular system, including effects on 
the electrocardiogram, vascular resistance, heart rate and the force of 
contraction of the heart (inotropy).  Compounds that increase the force of 
contraction of the heart can be harmful in patients with ischemic heart disease, 
whilst negative inotropes can induce symptoms of heart failure.  There is a range 
of non-clinical in vitro and in vivo assays used to detect inotropic effects of drugs.  
We have conducted a literature review of the in vitro assays and compared the 
findings from these with known effects on cardiac contractility in man.  There 
was a wide variety of assays used, ranging from perfuse whole hearts to isolated 
regions of the heart (papillary muscle, ventricle and atria), which were removed 
from a number of species (cat, guinea pig, rabbit and rat).  We conducted two 
analyses.  The first was investigating the concordance of the findings from the in 
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vitro assays at any concentration with those observed in man (an assessment of 
hazard identification) and the second was the concordance of the in vitro 
findings at concentrations tested up to 10-fold higher than those tested in the 
clinic.  We found that when used as a hazard identification tool, the available 
assays had good sensitivity (88%), although the specificity was not so good 
(60%), but when used as a risk management tool the sensitivity was 
considerable reduced (sensitivity 58 -70% and specificity 60%). 
 
These data would suggest that the available in vitro assays can be used as hazard 
identification tools for adverse drug effects on cardiac contractility, but there is a 
need for new assays to better predict the exposures in man that may cause a 
change in cardiac contractility and therefore better predict the likely therapeutic 
index of compounds prior to nomination of compounds for clinical development. 
 
1. Cardiac Contractility – A cardiovascular Risk factor. 
Compound attrition remains a major challenge for the pharmaceutical industry 
through out the drug discovery and development process.  Even in Phase II and 
Phase III clinical trials drug-related safety attrition accounts for 28% of all 
causes of compound failure, second to the lack of efficacy as the major cause of 
clinical attrition (Arrowsmith & Miller, 2013).  An adverse drug effect on the 
cardiovascular system is one of the major causes of safety-related attrition both 
in the non-clinical and clinical phases of drug development (Cook et al., 2014).  
This is despite the introduction of regulatory guidance that mandates the 
investigation of the effects of all new chemical entities on the cardiovascular 
system in a non-rodent species (ICH S7A).  Interestingly, the core package of 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 3 
safety pharmacology studies outlined in ICH S7A recommends an investigation 
of drug effects on blood pressure, heart rate and the electrocardiogram.  An 
investigation of effects on cardiac contractility is only recommended as part of 
the follow-up/supplementary studies. 
 
Drug effects on the cardiovascular system are complex with potential actions on 
vascular tone, heart rate, cardiac conduction and the force of contraction of the 
heart.  Furthermore, because of the complex neurohumoral control of the 
cardiovascular system drugs can have additional indirect effects on different 
parts of the cardiovascular system.  For example, vasodilator mechanisms can 
cause reflex changes in cardiac function, in the absence of a direct effect on the 
heart (Miller et al., 1975).  Thus in order to characterise drug effects on the 
cardiovascular system it is important to test for both direct and indirect effects 
on both the heart and vascular tone.   
 
Myocardial contractility reflects the ability of the heart to contract resulting in a 
change in force generation, which is independent of pre-load (sarcomere length).  
This increase in force against a constant after-load results in a greater volume of 
blood being ejected from the ventricle i.e. an increase in stroke volume.  
Relaxation of the heart is the process by which the heart muscle actively returns, 
after contraction, to its initial conditions of load and length and this is referred to 
as lusitropy.  A rapid and complete relaxation is required for cardiac output 
adaptation to changes in loading conditions, inotropic stimulation and heart rate.  
Thus it is possible for drugs to affect the active relaxation (lusitropic effects), 
contraction (inotropic) and rate of beating (chronotropic) of the heart. 
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Drug induced increases and decreases in cardiac contractility can be harmful 
depending on susceptible patient populations.  Drugs that have a direct positive 
inotropic effect on the heart will cause an increase in myocardial oxygen 
demand, which in normal healthy volunteers may be without consequence, but 
in patients with coronary artery disease such drugs can be associated with a risk 
of myocardial hypoxia.  Cardiac stimulants that act through inhibition of cAMP 
phosphodiesterases have been shown to increase mortality in patients with 
severe chronic heart failure (Packer et al., 1991).  Compounds that have negative 
inotropic activity, such as itraconazole, can induce symptoms of heart failure 
(Ahmad, Singer, & Leissa, 2001).  Thus, testing for drug effects on the 
contractility of the heart needs to take into account the potential patient 
population, but even in areas of high medical need, such as oncology, untoward 
effects on the cardiovascular system has become so significant that a new society 
has been formed to better advance the science in this area of oncology 
(International Cardiooncology Society, http://icosna.org). 
 
2. Non-clinical methods to detect drug effects on cardiac contractility. 
The isolated perfused mammalian heart preparation was established in 1897 by 
Oscar Langendorff.  These preparations are widely used to study the 
biochemistry of ischemia-reperfusion injury, drug effects on the ECG, heart rate 
and cardiac contractility (Skrzypiec-Spring, Grotthus, Szelag, & Schulz (2007).  
The isolated rat, guinea-pig and rabbit hearts have been used to study drug 
effects on the force of contraction of the heart using either a constant perfusion 
flow rate or constant perfusion pressure.  One of the advantages of the isolated 
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heart is that the rate of beating can be controlled and thus effects on the force of 
contraction, independent of rate, can be studied.  Furthermore, the preparation 
enables a direct effect on the heart to be confirmed, as opposed to reflex changes, 
which may be observed in the intact animal.  One of the disadvantages of the 
Langendorff preparation is that because there is essentially an open perfusion 
system there is no afterload resistance, unlike in the in vivo situation. For a 
recent detailed review on the Langendorff preparation refer to Bell et al (2011). 
 
In addition to the isolated perfused heart, a range of individual tissue 
preparations has been studied.  Cardiac muscle fibre studies have been utilized 
for many years to assess maximum upstroke velocity (Vmax) (Grant et al., 1978) 
as an indication of contractility.  In addition the isolated rat and rabbit ventricle 
are well suited for studying the inotropic effects of drugs (Ito et al., 1996) since 
the ventricles are the main contributors to inotropic state of the heart in vivo.  
Other preparations include the isolated atria, trabeculae and papillary muscle.  
The latter is often primarily used to study drug effects on the cardiac action 
potential and the force of contraction recorded as an additional end point 
(Honerjäger et al. 1986) making the preparation ideal for studying 
electromechanical coupling of the heart and the impact of drugs thereon. 
 
Drug effects on the force of contraction of the heart have been studied in a wide 
range of in vivo preparations.  The main advantages of these approaches are that 
they allow an assessment of cardiac contractility as one part of the overall 
haemodynamic profile of a compound, thus establishing an integrated 
cardiovascular assessment.  The main disadvantages is that some assessments of 
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cardiac contractility can be complex and it can be difficult to differentiate 
between a direct drug effect on the heart and an effect secondary to a change in 
vascular tone or heart rate.  The preferred approach to assessing a drug effect on 
cardiac contractility is through the measurement of the relationship between the 
ventricular pressure versus volume from which the wall stress versus strain 
relationship of the heart throughout the cardiac cycle can be estimated (Suga, 
Sagawa and Shoukas 1973).  The main advantage of such analysis is that they 
estimate drug effects on cardiac contractility independent of additional effects on 
heart rate and also pre- and after-load.  However, these techniques are complex 
and do not easily apply to the routine testing of new chemical entities and 
therefore a number of alternative techniques have been explored.  One of the 
most common approaches has been to use the maximal rate of pressure increase 
in the left ventricle during systole (LVdP/dtmax).  The introduction of a pressure 
transducer into the left ventricle, from which LVdP/dtmax is derived, has been 
used in many laboratory species including telemetered dog, monkey and mini-
pig (Markert et al 2007) and rats (Sato, Kandori and Sato 1994).  Although 
commonly used as a measure of cardiac contractility, LVdP/dtmax is influenced 
by heart rate and as such a drug-induced change in heart rate will affect 
LVdP/dtmax (Markert et al 2007).  In addition, LVdP/dtmax can be influenced by 
both pre- and after-load (Hamlin and del Rio 2012), although some authors have 
suggested that pre-load has minimal effects on LVdP/dtmax (Zimpfer and Vatner 
1981). 
 
Other, indirect methods for assessing drug-induced changes in cardiac 
contractility include the QA interval, the time between the Q-wave of the ECG 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 7 
and upstroke of aortic pressure (Cambridge and Whiting 1986).  Although the 
QA interval is a useful indicator of cardiac contractility (Norton, Iacono and 
Vezina 2009) it can be influenced by heart rate (Adeyemi et al 2009).  
Nevertheless, because it is a parameter that is easily derived from blood 
pressure and ECG recordings it can be used to exclude an effect on cardiac 
contractility if the test substance has minimal effects on heart rate. 
 
In order to accurately assess the effects of compounds on cardiac function, it is 
important to mimic the true in vivo cardiac muscle mechanics as closely as 
possible. Length-tension relationship is an important factor when investigating 
muscle mechanics in vitro. The length tension relationship relates to the 
arrangement of actin and myosin filaments in the muscle fibres.  At lower resting 
lengths there is a complete overlap between the thin and the thick filaments, 
which interferes with cross-bridge binding to active sites resulting in low tension 
upon muscle stimulation.  Maximal number of cross-bridges can be formed when 
the sarcomere length is optimal, producing highest tension.  Further increase in 
the sarcomere length results in decrease of tension as the size of the overlap 
zone and the number of potential cross-bridges is reduced (Shiels and White, 
2008).  
 
Length-tension relationships can be extrapolated to the whole heart mechanics.  
The extent of ventricular filling has a direct relationship with the pressure 
development in the ventricular muscle during contraction.  Frank-Starling law 
refers to the relationship of the force of ejection/pressure to the degree of 
ventricular filling/ length of muscle fibre at the end of diastole.  Increased 
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ventricular filling leads to extension of the muscle fibres in the ventricular wall, 
prestretch, before contraction occurs. This corresponds to the change in 
muscle/sarcomere length (Sperelakis, 2001).  
 
The choice of in vivo end points to assess drug effects on cardiac contractility 
very much depends on the nature of the experiment and the level of 
instrumentation that is acceptable.  As discussed above QA is a valuable, non-
invasive measure, in the absence of marked heart rate changes, whilst 
LVdP/dtmax appears an acceptable endpoint to most investigators and 
regulators. 
 
Currently, it is practically challenging to investigate pressure-volume behaviour 
on muscle mechanics in an in vivo setting. Therefore, in vitro muscle mechanics 
can be implemented by applying force-length dynamics. Contractile force is 
corresponding to the pressure against which the muscle is contracting and 
length relates to the initial muscle length, which is determined by the ventricular 
volume before the contraction takes place (Sperelakis, 2001).  
 
3.  In vitro testing methods of muscle mechanics 
The majority of the information on contractile dynamics has been provided by in 
vitro experimentation.  However, during in vitro experimentation, muscles are 
usually restricted and therefore do not behave as they would in situ.  Generally, 
only a certain aspect of muscle mechanics is investigated using a specific 
experimental technique, the results obtained should therefore be evaluated with 
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caution.  For example, studies have used constant muscle length (isometric), 
constant load (isotonic), constant velocity (iso-velocity) or recently work-loop 
studies to investigate muscle mechanics.   
 
4.  Isometric and isotonic contraction studies 
As mentioned before, an isometric testing protocol holds the muscle at a 
constant length throughout the electrical stimulation and force generation to 
investigate muscles’ ability to produce force.  Isometric contraction studies using 
cardiac muscle preparation have investigated the effects of compounds on 
muscle performance.  For example, doxorubicin-induced effects on the isometric 
contractile force were investigated in the human atrial trabeculae (Montaigne et 
al., 2011) and rat papillary muscles (Gharanei et al., 2012), which showed 
doxorubicin-induced reduction in the contractile force.  One of the major 
limitations of isometric contraction methods is that it does not reflect the in vivo 
muscle characteristic.  It is very rare for any muscle to remain at a constant 
length throughout the contractile process.  Dynamic activation and shortening 
are required for the muscle to perform work and therefore during contraction 
and relaxation the muscle will undergo a range of different length changes. 
Similarly, a muscle cannot shorten indefinitely, suggesting that eventual re-
lengthening will be required, therefore during in vivo contraction there will be a 
period where the muscle will be producing negative work (Josephson, 1993).  
 
During isotonic contractions the muscles are shortened and lengthened while 
maintaining a constant force.  Hence, the amount of work done on the muscle to 
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lengthen is the same as the amount of work done by the muscle to shorten.  
Muscle properties are evaluated by exploring the relationship between the 
muscle force and velocity of shortening.  Furthermore, the combination of force 
and length changes are unrealistic as shortening velocities and force production 
vary greatly during cyclical muscle movement. Unlike contractiling ventricles, 
during isometric and isotonic contraction studies no mechanical work is 
performed.  Moreover, it has been shown that isometric and isotonic contraction 
studies overestimate the amount of work undertaken by the muscle during 
contraction and relaxation in both skeletal and cardiac muscle (James et al., 
1996, Mellors et al., 2001). 
 
5.  Work-loop contraction studies 
It has been demonstrated that isometric and isotonic contraction studies poorly 
estimate the true in vivo muscle function (James et al., 1996, Mellors et al., 2001). 
Research by Josephson et al., (1985) developed the in vitro work-loop technique 
which resembled in vivo cardiac biomechanical motion more closely, as it 
considers multiple factors that determine muscle performance such as pre-
stretch effects, activation events and shortening dependent deactivation 
(Josephson, 1985).  Muscles usually work in antagonistic pairs thereby going 
through cyclical length changes during contraction and relaxation.  
 
The work-loop technique applies sinusoidal length changes to estimate in vivo 
muscle function.  It has been suggested that length changes that occur in the in 
vivo settings are not exactly in sinusoidal shape and form but are much more 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 11 
complex in nature.  However, the sinusoidal muscle has been considered to be a 
good and easy to implement generalisation of the in vivo muscle mechanics  
(Mellors et al., 2001, Mellors and Barclay, 2001). 
 
Ventricular contraction and relaxation can be separated into three phases in 
relation to the variation in muscle strain patterns; an initial isometric phase 
occurs during iso-volumic contraction at the start of ventricular systole, a 
shortening phase during ventricular ejection and finally re-lengthening phase 
that coincides with ventricular filling (Sperelakis, 2001).  Thus sinusoidal length 
changes during muscle activation and relaxation represent a closer simulation of 
in vivo contractions.  The work-loop technique can be used to combine sinusoidal 
length changes with phasic electrical stimulation, allowing power output of the 
muscles during contractions to be investigated under realistic physiological 
conditions (Josephson, 1985, Syme and Josephson, 1995, Josephson, 1993, James 
et al., 1996, Caiozzo, 2002). 
 
One of the key advantages of the work-loop technique is that it considers both 
passive and active properties of the muscle during contractions.  In the work-
loop the muscles are stimulated during lengthening, the muscles will continue to 
lengthen until the muscles produce maximum force.  During lengthening the 
muscles are not producing work; in contrast work is required for this phase of 
muscle contractions.  Therefore, the net-work required for the lengthening phase 
is negative (Josephson, 1985, James et al., 1996.  Following the rapid activation 
phase, the muscles undergo shortening, during which they produce work.  Net-
work during shortening phase is positive work (James et al., 1996, Josephson, 
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1993).  Parameters that can affect power output during sinusoidal contraction 
include cycle frequency used, the strain (% length change) of the muscle and the 
electrical stimulation phase and pattern (Josephson, 1993). 
 
By plotting the force produced by the muscle against muscle length, work and 
power output of the muscle can be calculated.  Unlike the isometric or isotonic 
contraction model, the work-loop technique also takes into account the work 
done by the muscle during shortening as well as the work required to re-extend 
the muscle during lengthening (Josephson, 1985, James et al., 1996).  This 
technique also incorporates changes in shortening velocity and the level of 
muscle activation during contractions as well as producing force and length 
changes that closely resemble papillary muscle dynamics in vivo (Semafuko and 
Bowie, 1975, Hirakawa et al., 1977).  Thus it is clear that the work-loop 
technique provides a more realistic physiological representation of cardiac 
muscle mechanics, allowing for a more accurate assessment of pharmacological 
compounds on cardiac muscle performance (Layland et al., 1995, Layland and 
Kentish, 1999, Layland and Kentish, 2000).  Studies from our laboratory have 
shown detrimental effects of doxorubicin on papillary muscle contraction using 
the work-loop technique.  We showed that clinically relevant concentration of 
doxorubicin caused a time-dependent decrease in muscle power output, 
maximum force and changes in the work-loop shapes (Gharanei et al., 2014). 
 
Therefore, the work-loop is considered to be an ideal choice for investigating 
muscle mechanics in health, stressed and diseased states, in particular when 
working with cardiac muscle.  
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6.  Cellular Impedance 
As discussed above, various cardiac preparations ranging from papillary muscle 
to Langendorff preparations have been used to investigate drug effects on 
cardiac inotropy.  In addition to these preparations, primary cardiomyocyte 
preparations have also been utilized to assess sarcomere length changes as a 
screen to assess contractility (Harmer et al, 2012).  Technical difficulties in 
obtaining sufficiently pure high yield cardiomyocyte preparations (Harding, Ali, 
Brito-Martins & Gorelik 2007) and the limited through-put of these methods 
often prevents their use for screening purposes during early drug development.  
 
Recently the impedance signals from various cells including neonatal rat 
myocytes and stem cell derived cardiomyocytes such as induced pluripotent 
stem cell-derived cardiomyocytes (iPSC-CM) and mouse embryonic stem cell 
derived cardiomyocytes have been investigated as surrogate markers for 
contractility (Scott et al, 2014).   It is beyond the remit of this review to discuss 
the current status of stem cell derived cardiomyocytes in pharmacology 
screening please refer to Khan et al (2013) and Kraushaar et al (2012) for a 
detailed review of  iPSC-CM in pharmacological screening.  Needless to say 
although iPSC-CM have been demonstrated to exhibit molecular and 
fundamental properties of the human heart (Himmel et al., 2013) detailed 
analysis has revealed a mixed fetal/adult expression pattern in general (Guo et 
al., 2011) and in particular immature expression of key proteins associated with 
calcium handling (Lee et al., 2011). 
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Overall results have been varied and responses from the stem cell derived 
cardiomyocytes have been shown to respond, on occasion, differently from those 
originating from established in-vitro and in-vivo models (Himmel 2013).  The 
assay also has inherent limitations with the inability to directly measure the 
velocity of contraction (Doherty et al 2013).  Although it has been shown that 
drug-induced cardiotoxic effects may be detected within this system, with the 
potential to identify cardiotoxicity hazard suitable for use in high throughput 
screening, this technique is an indirect measure of contractility and has provided 
contradicting results.  Cellular impedance does not provide insight into the 
intricate mechanisms implicated in contractility related cardiotoxicity and at this 
present time has not been demonstrated to be a useful tool to predict risk 
identification.  Overall the translational value of results from the cellular 
impedance assay is considered limited and not yet firmly established (Himmel 
2013). 
 
7. Literature review of the concordance between drug effects on cardiac 
contractility in man and in vitro assays of cardiac contractility. 
As discussed above there are a number of in vitro assays that have been used to 
evaluate the potential effects of compounds on cardiac contractility.  However, 
we are unaware of any evaluation of the predictivity of these assays for effects in 
humans.  In order to address this knowledge gap we have conducted a literature 
review on 22 compounds to understand the concordance between the non-
clinical assays and human outcome.  The human data was based on studies that 
measured drug effects on cardiac contractility, usually by echocardiography or 
cardiac catheterization.  The one exception to this was itraconazole in which the 
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clinical findings were based on clinical reports of symptoms of heart failure and 
the introduction of the FDA black box warning.  Some clinical studies measured 
the drug plasma concentrations within the cardiac contractility study whilst for 
other compounds the drug levels were estimated from published 
pharmacokinetic data.  The free drug levels were estimated using published 
human plasma protein binding data often found in the drugbank.ca website.  The 
non-clinical assessment was based solely on in vitro data.   
 
The literature search revealed the use of a wide range of assay types ranging 
from perfused whole hearts (Langendorff preparations), to isolated papillary 
muscle, ventricles and atria.  In addition, hearts were removed from a wide range 
of species, including rat, guinea pig, rabbit and cat, with the guinea pig being the 
most common species.  The heterogeneous nature of the dataset created several 
challenges with respect to defining the relationship between the in vitro assays 
and findings in man.  Firstly, there is no agreed standard for the definition of the 
magnitude of change that constitutes a drug effect in both the non-clinical assays 
and also effects in man.  Therefore we reported the author’s definition of  ‘a 
concentration effect’.  Secondly, there is no ‘standardised’ protocol for the 
conduct of the non-clinical assays making comparisons across studies 
challenging and therefore again we have reported the data as per the study 
report with no further analysis.  Thirdly, as previously mentioned the issue of 
species variation.  There was insufficient data to analyse individual species with 
respect to the concordance with man and so we have conducted the analysis 
independent of species and asked the question, does the non-clinical assays 
published in the literature predict effects in humans?   Despite these challenges 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 16 
we have attempted to address two critical questions.   How reliable are the 
available assays at identifying potential hazards with respect to effects on 
cardiac contractility in man and secondly can the available assays be used to 
manage a cardiac contractility risk?  As a hazard identification tool, safety 
scientists will use an assay to identify a potential drug hazard (in this case an 
effect on cardiac contractility) at any concentrations regardless of the relevance 
to the human exposure.  Thus, this question can be addressed by assessing the 
concordance between the clinical data and an in vitro cardiac contractility signal 
at any concentration in the latter.  Once a hazard has been identified it can be 
managed through a number of actions.  Firstly an understanding of the potential 
safety margin for the effect when compared to the predicted human exposure, 
secondly by understanding the mechanism of action (which should help define 
the human relevance) and thirdly by conducting additional studies, including an 
in vivo evaluation.  We have attempted to assess the value of the available in vitro 
cardiac contractility assays as risk management tools by assessing the 
concordance between the clinical data and the in vitro non-clinical data at a set 
multiple (~10-fold) of the clinical exposure.  Thus addressing the ability of the 
current assays to predict the likely human exposure that may cause an effect on 
cardiac contractility (i.e. ability to be used to predict the likely safety margin in 
man).   One observation from the review is that a number of drugs had a range of 
different potencies (>10-fold) across the various tissue types (e.g. amrinone, 
dobutamine, phenylephrine, cibenzoline and verapamil) and to a lesser extent on 
the same assay/species (e.g. disopyramide).  Thus, to assess the value as a risk 
management tool, we have taken a conservative approach and compared the 
most potent value in the non-clinical assay with the clinical findings. 
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The available assays appear to have good concordance for humans with respect 
to hazard identification.  Thus, the assays correctly identified, at some 
concentration, a range of human positive inotropes (including amrinone, digoxin, 
levosimendan, milrinone and enoximone) as well as negative inotropes (atenolol, 
flecainide, itraconazole and verapamil) and neutral compounds (captopril, 
metoprolol and phentolamine).  The exceptions to this were clonidine (negative 
inotrope in man but a positive inotrope in vitro), sunitinib (negative inotrope in 
man, but inactive on the guinea pig Langendorff) and the calcium channel 
blockers nifedipine and diltiazem which have been shown to have no effect on 
cardiac contractility in man at therapeutic concentrations and yet have a 
negative inotropic effect on a range of cardiac preparations.  The negative 
inotropic effect of clonidine in man is most likely due to it’s known effects on 
sympathetic drive (Cavero and Roach 1980) and not a direct effect on the heart 
and thus such an effect would not be expected to be detected in vitro.  Thus, it 
must be recognised that in vitro cardiac contractility assays will only detect 
direct drug effects on the heart and not those changes mediated through 
central/reflex mechanisms.  The adverse effects of sunitinib on cardiac function 
in man can take many days to develop (>22 days) (Orphanos, Ioannidis and 
Ardavanis 2009) and may involve some remodeling of the heart.  Thus drug 
effects on cardiac function that may be secondary to structural changes, as 
opposed to direct functional effects, may not be detectable in acute safety 
pharmacology studies.  The negative inotropic effects of nifedipine and diltiazem 
in vitro that was not observed in humans may be due to the reflex increase in 
cardiac contractility in man secondary to vasodilation, which could overcome the 
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direct negative inotropic action of these drugs.  Nevertheless, it is not surprising 
that some compounds will profile as ‘false positives’ in the non-clinical assay (an 
effect in vitro not observed in humans, in this case a negative inotropic effect). 
 
The ability of an assay to correctly predict the clinical outcome is referred to as 
the true positive (TP) rate (in this analysis it is slightly complicated because a 
true positive is a compound with a positive or negative inotropic effect in vitro 
which translates to the same effect in humans), whereas the false positive (FP) 
compounds are those with positive or negative inotropic activity in vitro that do 
not translate to man, true negatives (TN) have no effect in vitro nor in man 
(neutral compounds) and false negative (FN) compounds have no effect in vitro, 
but have an effect on cardiac contractility in man.  By comparing the true 
positive/negative and false positive/negative rate the assay sensitivity 
(TP/TP+FN) and specificity (TN/TN+FP) can be calculated.  As a hazard 
identification tool (an effect at any concentration in vitro), the assays performed 
well with a total of 15 true positives (all positive inotropes and all negative 
inotropes except clonidine and sunitinib), 2 false negatives (clonidine and 
sunitinib), 3 true negatives (captopril, metoprolol and phentolamine) and 2 false 
positives (diltiazem and nifedipine) (table 2).  These data would suggest that the 
sensitivity of the available non-clinical in vitro assays is good (88%), although 
the specificity relatively poor (60%).  This may be related to the small number of 
true negatives in this dataset. 
 
Although the in vitro assays identified all of the positive inotropes in man, there 
were some significant potency differences.  For example, pimobendan has very 
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potent inotropic effects in man (0.0005 μM free drug levels, table 1) and yet is 
relatively weak in vitro (10 to 50 μM, table 1).  Likewise, digoxin is a potent 
inotrope in man (0.001 μM) and much weaker in vitro (0.2 to 0.3 μM).  
Interestingly, levosimendan (0.013 μM) is less potent than pimobendan (0.0005 
μM) in man, but more potent in vitro (table 1).  Therefore it appears that the 
assays do not always predict the likely free drug levels that may affect cardiac 
contractility in humans.  This is an important aspect of risk management.  To 
assess the value as a risk management tool the concordance of the assays with 
man has been compared using the most potent non-clinical value with 
concentrations up to ~10-fold higher than those shown to have an effect on 
cardiac contractility in man.  As an example, amrinone has a positive inotropic 
effect in man following exposures to free drug levels of 15 μM and has a positive 
inotropic effect in vitro at 107 μM and is therefore considered a true positive (an 
effect in vitro at <150 μM, 10 x 15 μM).  In contrast pimobendan would be 
considered a false negative since there was no effect in vitro at concentrations up 
to 0.005 μM (10 x 0.0005 μM).  Using this type of analysis two compounds 
emerge as ‘threshold’, phenylephrine and enoximone, since these positive 
inotropes have effects in vitro at 20-fold and 13-fold the clinical concentrations.  
Thus the data has been reported with these compounds as both true positive and 
false negatives. 
 
Based on this analysis 12 true positives were identified (amrinone, dobutamine, 
levosimendan, milrinone, phenylephrine, enoximone, atenolol, cibenzoline, 
disopyramide, flecainide, itraconazole and verapamil), 5 false negatives (digoxin, 
glibenclamide, pimobendan, clonidine and sunitinib), 3 true negatives (captopril, 
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metoprolol and phentolamine) and 2 false positives (diltiazem and nifedipine) 
(table 3).  These data would suggest that, as a risk management tool, the 
sensitivity of the available non-clinical in vitro assays is lower (70%) than that as 
a hazard identification tool, although the specificity remains the same (60%).   If 
phenylephrine and enoximone were classified as false negatives the assay 
sensitivity would fall to 58%.  One potential criticism of using the most potent in 
vitro potency to compare with human data is that this may increase the false 
positive rate (i.e. an effect in vitro not observed in man), however this does not 
appear to be the case because only 2 false positive compounds were identified 
(diltiazem and nifedipine) and the potency estimates were quite consistent 
across the literature. 
 
In conclusion this literature review has identified a wide range of different in 
vitro assays, taken from different species, to assess drug effects on cardiac 
contractility.   The available assays appear to perform well as a hazard 
identification tool (sensitivity = 88%, specificity = 60%), but not so well at 
predicting the likely concentrations that may affect cardiac contractility in man 
(sensitivity = 58 - 70%, specificity = 60%).  Furthermore, the non-clinical assays 
did not effectively rank order the potency of compounds with the same mode of 
action (pimobendan and levosimendan).  Thus there appears to be a need for 
new and improved cardiac contractility assays that may better predict the 
concentrations that may affect cardiac contractility in man.  The data would also 
suggest that the available in vitro assays could be incorporated into an early 
safety testing strategy as hazard identification tools with the risk management of 
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any findings being dependent on the use of new assays e.g. in vitro work-loop 
assay and/or in vivo assessment. 
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Table 1.  Summary of literature search with inotropes of known clinical outcome 
and corresponding non-clinical in vitro data. 
 
Compound Human Data Estimated drug 
levels 
Non-clinical finding 
Positive inotropes 
Amrinone 600 mg daily to heart 
failure patients.1  
Intravenous dosing (0.5 to 
3.5 mg/kg) to heart failure 
patients.2  Inotropy 
measured by right heart 
catheterization. 
 
3.7 μg/ml2 = 15 
μM free. 
Guinea pig Langendorff 
(107 μM)3, rabbit papillary 
muscle (1000 μM)4, cat 
papillary muscle (300 and 
1000 μM).5,6 
Digoxin 20 μg/kg orally to healthy 
volunteers.7 Changes in the 
pre-ejection period index 
(PEPI) obtained from the 
systolic time intervals used 
as a measure of inotropism. 
 
0.5 to 1.0 
ng/ml7 = 0.001 
μM free. 
Guinea pig papillary muscle 
(300 nM)8 and cat papillary 
muscle ( 200 nM).9 
Dobutamine 20 μg/min infused into left 
coronary artery of healthy 
volunteers and heart 
failure patients.10  
Inotropism measured 
following left ventricular 
catheterization. 
 
200 ng/ml10 = 
0.5 μM free. 
Papillary muscle: cat (0.1 
μM)11, guinea pig (2 μM)6, 
cat (2 μM)6.  Guinea pig 
atria 2.6 μM12 and 0.5 μM.6 
Glibenclamide 5 mg glyburide to healthy 
volunteers.13  Inotropism 
measured radionucleotide 
ventriculography. 
 
637.9 nmol/l 
total14 = 0.06 
μM free. 
Rabbit Langendorff (10 
μM).15 
Levosimendan 3 mg levosimendan to 
healthy volunteers.  Effects 
measured by M-mode 
echocardiography.16 
 
180 ng/ml17 = 
0.013 μM free. 
 
Papillary muscle: rabbit (0.1 
μM)18 and guinea pig (0.1 
μM)19.  Guinea pig atria (0.1 
μM).19 
Milrinone 0.5 μg/kg/min to heart 
failure patients.  Inotropy 
measured by right heart 
catheterization.20 
 
352.3 ng/ml20= 
0.3 μM free. 
Langendorff: guinea pig (1.0 
μM)3, rabbit (7.7 μM)21.  
Guinea pig papillary muscle 
(8.0 μM).22 
Phenylephrine 20-200 μg /min infused 
into left coronary artery of 
healthy volunteers and 
Intracoronary 
concentration 
of 1.0 μM 
Papillary muscle:  guinea 
pig (10 μM)23, cat (1.0 μM)6.  
Rat atria (10 μM).24 
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heart failure patients.10  
Inotropism measured 
following left ventricular 
catheterization. 
 
total10  = 0.05 
μM free. 
Pimobendan 7.5 mg p.o. or 5 mg i.v. in 
healthy volunteers.  
Inotropy measured by 
echocardiography.25 
PKPD modeling 
suggests an 
effect 
concentration 
of 6.5 ng/ml25 = 
0.0005 μM free. 
Papillary muscle:  guinea 
pig (21 μM)22, (50 μM)26, 
(10 μM).27 
Enoximone 1.5 mg/kg i.v. to patients 
with coronary artery 
disease and left ventricular 
dysfunction.  Inotropy 
measured by 
echocardiography.28 
 
Total 
concentrations 
of 5 nmol/ml29 
= 0.75 μM free. 
Guinea pig Langendorff 
(10.0 μM).3 
Negative inotropes 
Atenolol 48 weeks of treatment with 
atenolol or irbesartan in 
patients with hypertensive 
LV hypertrophy.  Primary 
end point was Doppler-
derived myocardial 
performance index.30 
 
Total 
therapeutic 
concentrations 
of 550 ng/ml31 
= 0.2 μM free. 
Rat left and rat atria (1 
μM).32 
Cibenzoline Initial oral dose of 260 mg 
followed by 130mg b.i.d. in 
patients with nonsustained 
ventricular tachycardia and 
left ventricular dysfunction.  
Inotropy measured by right 
heart catheterization.33 
 
Total peak 
plasma 
concentrations 
of 1362 
ng/ml33 = 2.5 
μM free. 
Guinea pig papillary (30 
μM)34,  (35 μM)35, rabbit 
atria (1.32 to 5.26 μM).36 
Clonidine 1 μg/kg i.v. in healthy 
subjects.  Cardiac function 
measured by impedance 
cardiography.37Decreased 
Inotropy in heart failure 
subjects measured by 
isovolumic contraction.38 
 
Therapeutic 
plasma 
concentrations 
1.3 ng/ml39 = 
0.004 μM free. 
Guinea pig papillary – 
increased force contraction 
(5.0 μM).23 
Disopyramide 1.5 mg/kg i.v. to healthy 
volunteers.  Cardiac 
contractility measured by 
echocardiography.40 
 
Peak plasma 
concentrations 
of 6.8 μg/ml40 = 
9.0 μM free. 
Guinea pig papillary (10 
μM)41 and (100 μM).42 
Flecainide 800 mg orally to healthy Peak plasma Guinea pig papillary muscle 
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volunteers, cardiac 
contractility measured by 
echocardiography.43 
 
concentrations 
of 296 ng/ml43 
= 0.4 μM free. 
(5 μM)42, rat and rabbit 
ventricle (10 μM).44 
Itraconazole Clinical signs of heart 
failure.45 
Therapeutic 
plasma 
concentrations 
~2 μg/ml46 = 
0.03 μM free. 
Rabbit Langendorff (0.3 
μM).47 
Sunitinib Reductions in left 
ventricular ejection 
fraction inpatients with 
metastatic renal cell 
carcinoma.48 
 
Therapeutic 
plasma 
concentrations 
~100 ng/ml49 = 
0.01 μM free. 
No effect on guinea pig 
Langendorff at 0.3 μM.50 
Verapamil 10 mg i.v. in patents with 
coronary artery disease 
and rheumatic valvular 
disease.  Inotropy 
measured by heart 
catheterization.51 
 
Plasma 
concentrations 
of 40 ng/ml 
following 10 
mg i.v. 52 = 0.01 
μM free. 
Guinea pig Langendorff 
(0.03 μM)50; Papillary 
muscle, rat (0.5 μM)53 and 
guinea pig (0.8, 0.5 μM).34,54 
Neutral compounds 
Captopril 50 mg b.i.d. in heart failure 
patients, cardiac 
contractility measured by 
echocardiography.55 
 
Free drug 
levels of 300 
ng/ml = 1.06 
μM free.56 
Langendorff  - no effect in 
guinea pig (1.0 μM)57 or rat 
(0.4 μM).58 
Diltiazem 120 mg p.o. in coronary 
infarction patients.  
Inotropy measured by 
heart catheterization.59 
Therapeutic 
plasma 
concentrations 
~130 ng/ml46 = 
0.06 μM free. 
Langendorff – decreased 
contractility in rat (1.0 
μM)60and rabbit (1.0 μM)61.  
Reduced contractility in 
guinea pig papillary muscle 
(3.0 μM).54 
Metoprolol 50 mg b.i.d. to healthy 
subjects, cardiac 
contractility measured by 
echocardiography.62 
Total drug 
levels of 500 
nM following 
100 mg b.i.d. = 
0.2 μM free 
following 50 
mg b.i.d.63 
No effect on guinea pig 
Langendorff (1.0 μM).64 
Nifedipine 20 mg p.o. in coronary 
infarction patients.  
Inotropy measured by 
heart catheterization.59 
Therapeutic 
plasma 
concentrations 
~100 ng/ml46 = 
0.01 μM free 
Decrease force -  guinea pig 
papillary muscle (0.1 μM).54 
Phentolamine 200 μg /min infused into 
left coronary artery of 
healthy volunteers and 
Intracoronary 
concentration 
of 5.0 μM 
No effect on rat and rabbit 
papillary muscle (1.0 
μM).65,66 
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heart failure patients.10  
Inotropism measured 
following left ventricular 
catheterization. 
 
total10  = 2.25 
μM free. 
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Table 2 2x2 Contingency table for the concordance of in vitro cardiac 
contractility assays with human findings regardless of concentration. 
 
Non-clinical 
outcome 
 Clinical Outcome 
Inotropic effect No inotropic effect 
No inotropic effect 3 2 
Inotropic effect 2 15 
 
 
Table 3 2x2 Contingency table for the concordance of in vitro cardiac 
contractility assays with human findings by comparing in vitro concentrations up 
to 10-fold higher than those tested in man . 
 
Non-clinical 
outcome 
 Clinical Outcome 
Inotropic effect No inotropic effect 
No inotropic effect 3 5 
Inotropic effect 2 12 
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